Nuclein key facts
- Developer of a rapid PCR testing system designed to deliver lab results at the point of care.
- It has raised $67.3M across 5 recorded rounds; the latest was Debt ($1.3M) in Jun 2026.
- Notable investors include Alan Richey, ACC Bioscience Incubator, David Shockley, Dr. John Butler, Jason Dorsey — 9 tracked in total.
- Nuclein has filed 10 Form Ds with the SEC since 2019, most recently Dec 2025 ($14.9M sold to 42 investors).
- Status: Privately Held (backing).
- ·Watch Nuclein: the Monday email on marks, rounds and moves
Nuclein funding rounds
5 roundsHow much has Nuclein raised?
Nuclein has raised $67.3 million across 5 recorded rounds since 2019. The largest was a $9.4 million early-stage round in Jan 2025; the most recent was a $1.3 million debt round in Jun 2026.
Nuclein has filed 10 Form Ds with the SEC since 2019, most recently in Dec 2025 ($14.9 million sold to 42 investors).
Nuclein investors
9 investors are on record for Nuclein, including Alan Richey, ACC Bioscience Incubator, David Shockley and Dr. John Butler. The debt round in Jun 2026 drew 2 investors.
About Nuclein
Developer of a rapid PCR testing system designed to deliver lab results at the point of care. The company's system offers a DASH Rapid PCR (Polymerase Chain Reaction) system of care instrument with test cartridges that can run a wide variety of sample types, enabling healthcare providers to make treatment decisions with minimal hands-on time.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 69
- Website
- nuclein.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Nuclein doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.